ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,119.40
0.79%
US Tech 100
21,235.20
1.50%
다우존스 지수
44,908.68
0.06%
Bitcoin
105,264.24
0.51%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Ironwood Pharmaceuticals Inc (IRWD) 시세

Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc (IRWD)

NASDAQ
2.365
0.065
( 2.83% )
업데이트: 00:59:27
15분 지연

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

주요 통계 및 세부정보

가격
2.365
매수가
2.36
매도가
2.37
거래량
1,020,930
2.3301 일간 변동폭 2.54
2.25 52주 범위 15.70
market_cap
378.467M
전일 종가
2.30
개장가
2.3907
최근 거래 시간
100
@
2.3656
(average)
마지막 거래 시간
00:59:30
재정 규모
US$ 2,431,734
VWAP
2.3819
평균 볼륨(3m)
2,145,445
발행 주식
160,028,388
배당수익률
-
주가수익률
-0.38
주당순이익(EPS)
-6.26
매출
442.74M
순이익
-1B

Ironwood Pharmaceuticals Inc 정보

Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic const... Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.ironwoodpharma.com
본부
Wilmington, Delaware, USA
설립됨
-
Ironwood Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker IRWD. The last closing price for Ironwood Pharmaceuticals was US$2.30. Over the last year, Ironwood Pharmaceuticals shares have traded in a share price range of US$ 2.25 to US$ 15.70.

Ironwood Pharmaceuticals currently has 160,028,388 shares in issue. The market capitalisation of Ironwood Pharmaceuticals is US$368.07 million. Ironwood Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.38.

IRWD 최신 뉴스

추가 뉴스

Form 4 - Statement of changes in beneficial ownership of securities

30 1월 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

30 1월 2025
Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities

30 1월 2025
Edgar (US Regulatory)

Form 8-K - Current report

30 1월 2025
Edgar (US Regulatory)

Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future

– Data from open label extension study of apraglutide demonstrate further increase in patients achieving enteral autonomy – – Initiated rolling NDA submission, now to include long-term extension...

30 1월 2025
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

23 1월 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

23 1월 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

23 1월 2025
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

28 12월 2024
Edgar (US Regulatory)

Form 8-K - Current report

06 12월 2024
Edgar (US Regulatory)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-1.435-37.76315789473.84.032.2530430372.74987451CS
4-1.915-44.74299065424.284.7752.2522906763.58396493CS
12-2.355-49.89406779664.725.12882.2521454453.80894134CS
26-4.575-65.92219020176.947.082.2519685794.1890231CS
52-11.325-82.724616508413.6915.72.2527215647.20784806CS
156-8.515-78.262867647110.8815.72.2525394829.66138404CS
260-9.715-80.422185430512.0815.72.25230034210.15596401CS

IRWD - Frequently Asked Questions (FAQ)

What is the current Ironwood Pharmaceuticals share price?
The current share price of Ironwood Pharmaceuticals is US$ 2.365
How many Ironwood Pharmaceuticals shares are in issue?
Ironwood Pharmaceuticals has 160,028,388 shares in issue
What is the market cap of Ironwood Pharmaceuticals?
The market capitalisation of Ironwood Pharmaceuticals is USD 368.07M
What is the 1 year trading range for Ironwood Pharmaceuticals share price?
Ironwood Pharmaceuticals has traded in the range of US$ 2.25 to US$ 15.70 during the past year
What is the PE ratio of Ironwood Pharmaceuticals?
The price to earnings ratio of Ironwood Pharmaceuticals is -0.38
What is the cash to sales ratio of Ironwood Pharmaceuticals?
The cash to sales ratio of Ironwood Pharmaceuticals is 0.85
What is the reporting currency for Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Ironwood Pharmaceuticals?
The latest annual turnover of Ironwood Pharmaceuticals is USD 442.74M
What is the latest annual profit for Ironwood Pharmaceuticals?
The latest annual profit of Ironwood Pharmaceuticals is USD -1B
What is the registered address of Ironwood Pharmaceuticals?
The registered address for Ironwood Pharmaceuticals is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Ironwood Pharmaceuticals website address?
The website address for Ironwood Pharmaceuticals is www.ironwoodpharma.com
Which industry sector does Ironwood Pharmaceuticals operate in?
Ironwood Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
TCTMTCTM Kids IT Education Inc
US$ 0.9901
(446.71%)
408.09M
TDTHTrident Digital Tech Holdings Ltd
US$ 1.7802
(87.39%)
18.57M
REBNReborn Coffee Inc
US$ 3.23
(59.11%)
6.01M
CYCNCyclerion Therapeutics Inc
US$ 3.55
(39.76%)
53.65M
SOPASociety Pass Inc
US$ 1.2973
(31.84%)
2.46M
ENVBEnveric Biosciences Inc
US$ 2.10
(-46.15%)
957.39k
NIVFNewGenIvf Group Ltd
US$ 0.1453
(-43.90%)
7.39M
BHILBenson Hill Inc
US$ 2.28
(-42.28%)
1.82M
SHOTWSafety Shot Inc
US$ 0.11
(-26.12%)
101
CYNCYNGN Inc
US$ 0.2575
(-22.74%)
8M
TCTMTCTM Kids IT Education Inc
US$ 1.01
(457.70%)
408.69M
RIMEAlgorhythm Holdings Inc
US$ 0.0294
(20.49%)
230.12M
CLEUChina Liberal Education Holdings Ltd
US$ 0.1581
(6.68%)
112.43M
NVDANVIDIA Corporation
US$ 126.535
(1.51%)
111.85M
RGTIRigetti Computing Inc
US$ 13.9256
(13.22%)
92.07M

IRWD Discussion

게시물 보기
ProLiberty ProLiberty 6 월 전
Possible buy below $5? Any chance the VectivBio acquisition ends up not being as horrible as it currently appears? When might the acquired asset begin to generate revenue?
👍️0
Monksdream Monksdream 10 월 전
IRWD under $10
👍️0
philaya philaya 10 월 전
sold...
fast trading.
👍️0
philaya philaya 10 월 전
Using radar...
Got this today
👍️0
Dubster watching Dubster watching 11 월 전
B$9.01
👍️0
BabySealHugger BabySealHugger 4 년 전
Hearing rumblings of IRWD this week. Anyone else?
👍️0
whytestocks whytestocks 4 년 전
Just In: $IRWD Ironwood Pharmaceuticals Inc (IRWD) Q3 2020 Earnings Call Transcript

Image source: The Motley Fool. Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Q3 2020 Earnings Call Nov 6, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Ironwood Pharmaceuticals Inc (IRWD) Q3 2020 Earnings Call Trans...

Find out more IRWD - Ironwood Pharmaceuticals Inc (IRWD) Q3 2020 Earnings Call Transcript
👍️0
whytestocks whytestocks 4 년 전
Just In: $IRWD Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment

– Trial did not achieve statistically significant improvement in heartburn severity (primary endpoint) – – Ironwood plans to implement organizational restructuring, resulting in expected headcount reduction of approximately 100 full-time employees, or near...

In case you are interested IRWD - Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment
👍️0
whytestocks whytestocks 6 년 전
News: $IRWD Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

– Phase IIIb study met all primary and secondary endpoints with statistical significance and demonstrated that linaclotide improved the overall abdominal symptoms of bloating, pain and discomfort in adults with IBS-C – – Results further support the efficacy and s...

Got this from https://marketwirenews.com/news-releases/ironwood-and-allergan-report-positive-topline-data-from-phase-iiib-trial-of-linzess-xae-linaclotide-in-adults-with-irritable-bowel-syndrome-with-constipation-ibs-c--8377600.html
👍️0
ClayTrader ClayTrader 6 년 전
* * $IRWD Video Chart 05-17-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
stocktrademan stocktrademan 6 년 전
IRWD buy 11.365

https://www.ironwoodpharma.com/



normal chart







log chart






👍️0
chemist99 chemist99 6 년 전
epilogue

SGYP down to 3 pennies after hours today

the signs were all there, but you had to be willing to read them.

if there is a list somewhere, like, "always go on the opposite end of the trade for all recommendations from these institutions" - most of the SGYP institutional investors should definitely be on it IMHO.
👍️0
chemist99 chemist99 6 년 전
How did that work out for you;)
👍️0
chemist99 chemist99 7 년 전
knew all too well what was going on behind the Synergy scenes;

http://www.nj.com/business/index.ssf/2012/08/bristol-myers_drug_flop_erases.html


if you make a multinational company lose a couple billion $ in short order & leave them stuck with trial deaths, AND expect anyone in the pharmaceutical industry ever to trust you again, you need to have your head examined imo. he's probably looking under his car every morning...

there's a really nice package deal available for you though from the experienced crew, if you're still game for it:

Synergy, $6 in January, now on sale at $1.90, Trovagene, went public at $24, now marked down to 51 cents for quick clearance, and ContraVir, $5 as recently as 2015, but now available for just 49 cents! Yes, you get all three of these made-to-be-sold companies for just $2.90! And, if you act now, we'll throw in 10 shares of Callisto Pharmaceuticals, a company which sank beneath the waves with Cap'n Gary at the helm!

👍️0
chemist99 chemist99 7 년 전
Enjoy the front row seat to the final act of the drama, sure was expensive enough...
👍️0
chemist99 chemist99 7 년 전
Q.e.d.
👍️0
Inoviorulez Inoviorulez 8 년 전
https://seekingalpha.com/article/4089539-ironwood-will-press-good-fight-gerd
👍️0
chemist99 chemist99 8 년 전
:(
👍️0
chemist99 chemist99 8 년 전
:)
👍️0
chemist99 chemist99 9 년 전
Brilliant !
👍️0
brownsfan407 brownsfan407 9 년 전
I did 10,000 shares on that one, didn't get in at the low, but out close to the top. Flipped it into sgyp in the low 3's
👍️0
chemist99 chemist99 9 년 전
thanks for bringing it to my attention! that was nice, ~7.30s to $10.24 in less than a month, 30+% !
Hope you didn't miss it :) ?
👍️0
brownsfan407 brownsfan407 9 년 전
you were right, we saw 7's this week. 52 week low
👍️0
chemist99 chemist99 9 년 전
SGYP short volume 25 million plus now...looks like the hedgefunds are in the business to lose money then ?
👍️0
brownsfan407 brownsfan407 10 년 전
under 10 coming your way soon. the trend is your friend
👍️0
brownsfan407 brownsfan407 10 년 전
IRWD, 10.71 new 52 week low fact, not rant
8.00 in September lows
👍️0
chemist99 chemist99 10 년 전
no pain data, skewed side effect profile = no partner IMO.

no partner = slim chance, if any, of competing in the marketplace for a primary care drug with an army of people promoting the first-to-market competitor, IMO.

simple as that.

rant all you want. doesn't change the fact that Phase III CIC data are out - and still no buyout & no partnership despite the "hey we're for sale" press article LOL.

that, and the low (~30%) institutional ownership of SGYP compared with IRWD (~100%), combined with the ~22 mill. short volume for SGYP speak volumes...



👍️0
brownsfan407 brownsfan407 10 년 전
IRWD pennies of 51 week low, while market booms. Stock price heading in the same direction as the diarrhea it causes. despite misinformation by IRWD propagandist.. BTW, I bought a boatload of warrants at .36, now 4.00. I can be very patient for the next explosion. 2 phase 3 results and an NDA by year end
👍️0
brownsfan407 brownsfan407 10 년 전
from an IRWD board? nice, just a little biased. Don't try to be naïve, you have no idea what is going on behind the scenes. and like I said you have lots of holders, but yahoo stats says 3 percent own over 5 percent, and that 3 percent includes insider holdings. Everyone owns a little. Cerrone TOOK 1/2 year with inhibitex, to get top buck, we have only been a month here. 4 catalysts by year end. we are up 165 percent, you? your short at 4 dollars is a FAILED trade
👍️0
chemist99 chemist99 10 년 전
sooner or later the Wall Street hysteria, fanned by a couple of hyperbolic analyst op ed pieces, will be over; - the music will stop, people will wake up & valuations will adjust to reality. they always do.

I quote a comment of someone from "the trenches" posted on the IRWD CP board, who puts it in quite simple (& blunt) terms:

anonymous, Jul 22, 2015 at 9:37 AM
(quote) ...." Less diarrhea, yes but with that is less efficacy. You can't treat cic with no diarrhea and have the same efficacy. So you think you can hire a third of the reps ? So roughly 1 rep per state to grow the constipation market of 50 million? This is a primary care drug linzess has over 3000 people promoting it. When it is all said and done 80 percent of volume will come from pcp. You need a partner and despite your so called stellar efficacy and no side effects no one is stepping up. No pain data and skewed side effect data equals no partner. We developed plecanatide and linaclotide and kept linzess. I'm gonna go with the MIT scientists who discovered GCC on this one..."

http://www.cafepharma.com/boards/threads/we-should-buy-synergy.583049/

👍️0
brownsfan407 brownsfan407 10 년 전
I don't know the answer, but do you think they are happy with the price DEpreciation, under 11, it has been YEARS since it has been that low
👍️0
chemist99 chemist99 10 년 전
IRWD:
% of Shares Held by Institutional & Mutual Fund Owners: 110%
% of Float Held by Institutional & Mutual Fund Owners: 112%
Number of Institutions Holding Shares: 163

SGYP:
% of Shares Held by Institutional & Mutual Fund Owners: 29%
% of Float Held by Institutional & Mutual Fund Owners: 32%
Number of Institutions Holding Shares: 90

source: Yahoo finance 07/22/15
👍️0
brownsfan407 brownsfan407 10 년 전
% of Shares Held by All Insider and 5% Owners: 2 percent. surprisingly low. lots with their toes in the water, but no ringing endorsements
👍️0
brownsfan407 brownsfan407 10 년 전
I can explain the price drop in facts, but I can't help you to understand it
👍️0
brownsfan407 brownsfan407 10 년 전
Chemist, you the only one here? Looks like it
👍️0
brownsfan407 brownsfan407 10 년 전
but our price is going up, I am sorry, which way is this price going? It is not going to be long before our price eclipses yours
👍️0
chemist99 chemist99 10 년 전
Sgyp new short volume ~ 22 mill; - go figure ??
👍️0
brownsfan407 brownsfan407 10 년 전
chemist, short up to 17 mill, too bad you can't use your moniker to reformulate this drug into something better, but then again, what chemistry do you need to use a virus?
👍️0
brownsfan407 brownsfan407 10 년 전
hot 6 page found in nature thing working for you? I am having trouble with my pixels, did wedbush lower the target to 11? that's lower than the current price
👍️0
brownsfan407 brownsfan407 10 년 전
6/15 was days before the phase 3 results. I bet some more shorted the 9 down to 8 to cover the earlier bad trade. We hire 2 more big guns today, and the pump articles and increasing price targets are like ants around a popsicle on a picnic, they are everywhere. Synergy will do ma secondary at 13, pay back the loan, and actually lower their share count, and knock off the interest
👍️0
chemist99 chemist99 10 년 전
yes, IRWD short interest up to ~16 million shares, but SGYP up even more to about ~21.5 million shares per 06/15 :
http://www.nasdaq.com/symbol/sgyp/short-interest

the hedge funds must be in the business to lose money, I guess...
👍️0
brownsfan407 brownsfan407 10 년 전
Chemist, Last SI up 2 million, are there folks betting on this going down. are you hedged? Sgyp set to double
👍️0
brownsfan407 brownsfan407 10 년 전
How about your long position here? 1/3 the diarrhea rate for plecanatide, and filing NDA in November. Has to severely stunt the growth here. What is the adage, the market is forward looking? However, maybe you can clarify. The guy who took IRWD through the NDA process, does he still work for you?
👍️0
brownsfan407 brownsfan407 10 년 전
In a few months the ticker symbol for Synergy may not exist, in a perfect world
👍️0
chemist99 chemist99 10 년 전
No short no loss. Let's compare notes again in a few months. Enjoy it while it lasts??
👍️0
brownsfan407 brownsfan407 10 년 전
what did you lose on the short? 6 bucks per share? and now, your long shares here are severely compromised. I would have some compassion for you if it were not for your past smugness and haughtiness
👍️0
brownsfan407 brownsfan407 10 년 전
Game, set, match, plecanatide is clearly better. Cannot dispute the numbers, as the 600 rode the 89 percent gain
👍️0
chemist99 chemist99 10 년 전
oh well, it served it's purpose, I suppose :)
👍️0
brownsfan407 brownsfan407 10 년 전
check out lpcn, oral trt, NDA BY Q3, pre-term birth PILL too. Low float monster
👍️0
chemist99 chemist99 10 년 전
lol.

a little knowledge can be a dangerous thing.
👍️0

최근 히스토리

NASDAQ
IRWD
Ironwood Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지